Get the Stockscreener App
39.15
1.35%
0.51
Terns Pharmaceuticals Inc stock is traded at $39.15, with a volume of 767.33K.
It is up +1.35% in the last 24 hours and up +14.81% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$38.64
Open:
$39.14
24h Volume:
767.33K
Relative Volume:
0.24
Market Cap:
$4.26B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-29.66
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+10.81%
1M Performance:
+14.81%
6M Performance:
+499.69%
1Y Performance:
+802.30%
1-Day Range:
$37.63
$39.54
1-Week Range:
$35.45
$39.60
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
39.15 | 4.20B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.51 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.26 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.37 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.97 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.06 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Leerink Partners | Outperform |
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target - marketscreener.com
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating By Investing.com - Investing.com Canada
Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - MarketBeat
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating - Investing.com
VIX Spike: What are Terns Pharmaceuticals Incs technical support levels2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high? - MSN
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? - sharewise.com
Terns Pharmaceuticals, Inc. $TERN Stock Position Increased by AlphaQuest LLC - MarketBeat
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update - Sahm
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Terns Pharmaceuticals (TERN) Valuation Check After Expanded Global Rights To TERN-701 - Yahoo Finance
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule - TradingView
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders - Sahm
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment - Finviz
Terns Pharmaceuticals patent discloses GIPR antagonists - BioWorld MedTech
What is Terns Pharmaceuticals Inc. s 5 year growth outlook2025 Historical Comparison & Daily Profit Maximizing Trade Tips - mfd.ru
Terns Pharmaceuticals Expands Global Rights to TERN-701 - TipRanks
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal - BioPharma Dive
Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights - Investing.com
What technical signals suggest for Terns Pharmaceuticals Inc. stockQuarterly Trade Summary & Low Risk Profit Maximizing Plans - bollywoodhelpline.com
Wall Street forecasts 42.31% upside to Terns Pharmaceuticals, Inc. (TERN) - MSN
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise - Sahm
Insider Selling: Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $2,548,525.43 in Stock - MarketBeat
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) - Finviz
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map - TechStock²
Terns Pharmaceuticals (NASDAQ:TERN) Trading Up 10.4%Should You Buy? - MarketBeat
Aug Patterns: Can Terns Pharmaceuticals Inc stock sustain institutional interestJuly 2025 Final Week & Consistent Profit Trade Alerts - Bộ Nội Vụ
J.P. Morgan: Terns Looks To Take Flight With TERN-701 In 2026 - Citeline News & Insights
William Blair reiterates Outperform rating on Terns Pharmaceuticals stock By Investing.com - Investing.com Canada
Terns Pharmaceuticals (TERN) Valuation After Encouraging TERN 701 CML Data And Capital Raise Powered Development Plans - Yahoo Finance
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN) - Finviz
Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3%Here's Why - MarketBeat
Assessing Terns Pharmaceuticals (TERN) Valuation After Recent Share Price Swings And Elevated Price To Book Ratio - Sahm
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Terns Pharmaceuticals (TERN) - The Globe and Mail
How Rhythm Pharmaceuticals, Inc. stock performs during market volatility - Улправда
Tern Pharmaceuticals (TERN) soars 630% on CML treatment best-in-class potential - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Why Terns Pharmaceuticals Inc. stock could see breakout soonEarnings Beat & Consistent Return Investment Signals - ulpravda.ru
Why Terns Pharmaceuticals Inc. stock could be next big winnerEarnings Recap Summary & Daily Entry Point Trade Alerts - Улправда
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative - Sahm
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Star Tribune - FinancialContent
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.65%
2.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):